Skip to content

RSYR for Fatigue Reduction in Cancer Fatigue Caused by Chemotherapy

A Multicenter, Randomized, Double-blind Clinical Trial of TCM in Reducing CRF Caused by Chemotherapy in Cancer Patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05229029
Acronym
TCM
Enrollment
196
Registered
2022-02-08
Start date
2020-04-02
Completion date
2024-06-30
Last updated
2024-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related Problem/Condition

Keywords

Chemotherapy, Fatigue, Cancer

Brief summary

This is a multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of Chinese herbal compound in improving fatigue symptoms and quality of life in patients with chemotherapy.

Detailed description

In this study, symptomatic indicators and quality of life were used as the main evaluation indicators. Patients with moderate to severe CRF who received dual drug chemotherapy were given traditional Chinese medicine compound and placebo intervention respectively. The data of fatigue symptoms, quality of life, sleep quality, blood routine test, liver and kidney function were observed and compared, so as to verify the traditional Chinese medicine compound prescription in improving the CRF symptoms and quality of life of chemotherapy patients validity.

Interventions

TCM herbs:White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.

DRUGPlacebo

Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs

Sponsors

Peking University Cancer Hospital & Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Malignant tumor patients with pathological diagnosis * Men and women aged 18-75 * KPS score ≥ 70, expected survival time more than 6 months * The function of heart, lung, liver and kidney was normal * Hemoglobin ≥ 8g * Neuroendocrine function is normal * BMI ≥ 18.5. * Cancer pain, VAS score \< 3 * Fatigue score ≥ 4 * syndrome differentiation is deficiency of Qi and blood

Exclusion criteria

* Brain metastases with Symptomatic * Mental disease * Severe infection * Insomniacs * Pregnant or lactating women

Design outcomes

Primary

MeasureTime frameDescription
Fatigue score21 daysSelf-assessed 24-hour fatigue symptom score. According to the NCCN fatigue guide, the score is 0-10 points, 0 points means no fatigue, 10 points means the most serious fatigue that can be imagined.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026